Contact

All Stories

  1. Assessment of SARS-CoV-2 immune escape using antigenic cartography combined with experimental challenge studies

    Article • npj Vaccines, January 2026, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  2. Preferential boosting of SARS-CoV-2 Omicron lineage-specific immune responses by monovalent XBB.1.5 vaccination

    Article • November 2025, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  3. SARS-CoV-2 cross-reactive B-cells outnumber seasonal coronavirus spike-specific clones at the end of the COVID-19 pandemic

    Article • October 2025, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  4. Human organoid models to study coronavirus infections of the respiratory tract

    Article • Current Opinion in Virology, September 2025, Elsevier

    Professor (Associate) Bart L. Haagmans

  5. Assessment of SARS-CoV-2 immune escape using antigenic cartography combined with experimental challenge studies

    Article • August 2025, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  6. The role of gowns in preventing nosocomial transmission of respiratory viruses: a systematic review

    Article • Journal of Hospital Infection, June 2025, Elsevier

    Professor (Associate) Bart L. Haagmans

  7. Long-term culture of chicken tracheal organoids for the purpose of avian influenza virus research

    Article • Virology Journal, April 2025, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  8. Variable DPP4 expression in multiciliated cells of the human nasal epithelium as a determinant for MERS-CoV tropism

    Article • Proceedings of the National Academy of Sciences, March 2025, Proceedings of the National Academy of Sciences

    Professor (Associate) Bart L. Haagmans

  9. A pan-orthohantavirus human lung xenograft mouse model and its utility for preclinical studies

    Article • PLoS Pathogens, January 2025, PLOS

    Professor (Associate) Bart L. Haagmans

  10. A Global Collaborative Comparison of SARS-CoV-2 Antigenicity Across 15 Laboratories

    Article • Viruses, December 2024, MDPI AG

    Professor (Associate) Bart L. Haagmans

  11. Characterization of a SARS-CoV-2 Omicron BA.5 direct-contact transmission model in hamsters

    Article • npj Viruses, November 2024, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  12. Detection of Double-Stranded RNA Intermediates During SARS-CoV-2 Infections of Syrian Golden Hamsters with Monoclonal Antibodies and Its Implications for Histopathological Evaluation of In Vivo Studies

    Article • International Journal of Molecular Sciences, October 2024, MDPI AG

    Professor (Associate) Bart L. Haagmans

  13. Safety, immunogenicity, and optimal dosing of a modified vaccinia Ankara-based vaccine against MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trial

    Article • The Lancet Infectious Diseases, October 2024, Elsevier

    Professor (Associate) Bart L. Haagmans

  14. Resistance to SARS-CoV-2 infection in camelid nasal organoids is associated with lack of ACE2 expression

    Article • npj Viruses, September 2024, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  15. Advancing COVID-19 diagnostics: rapid detection of intact SARS-CoV-2 using viability RT-PCR assay

    Article • Microbiology Spectrum, July 2024, ASM Journals

    Professor (Associate) Bart L. Haagmans

  16. Characterization of a SARS-CoV-2 Omicron BA.5 direct-contact transmission model in hamsters

    Article • July 2024, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  17. Dissecting humoral immune responses to an MVA-vectored MERS vaccine in humans using a systems serology approach

    Article • iScience, July 2024, Elsevier

    Professor (Associate) Bart L. Haagmans

  18. Virus neutralization assays for human respiratory syncytial virus using airway organoids

    Article • Cellular and Molecular Life Sciences, June 2024, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  19. Profiling the SARS-CoV-2-specific T-cell response

    Article • The Lancet Infectious Diseases, June 2024, Elsevier

    Professor (Associate) Bart L. Haagmans

  20. Nachweis doppelsträngiger RNS-Intermediate bei verschiedenen Varianten des schweren akuten respiratorischen Syndrom-Coronavirus-2 (SARS-CoV-2) in formalinfixiertem, paraffineingebettetem Lungengewebe experimentell infizierter Hamster

    Article • Tierärztliche Praxis Ausgabe K Kleintiere / Heimtiere, June 2024, Thieme Publishing Group

    Professor (Associate) Bart L. Haagmans

  21. Direct comparison of SARS-CoV-2 variant specific neutralizing antibodies in human and hamster sera

    Article • npj Vaccines, May 2024, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  22. Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters

    Article • Nature Communications, May 2024, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans, Douwe Postma

  23. Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays

    Article • Science Translational Medicine, May 2024, American Association for the Advancement of Science

    Professor (Associate) Bart L. Haagmans

  24. An updated framework for SARS-CoV-2 variants reflects the unpredictability of viral evolution

    Article • Nature Reports Stem Cells, May 2024, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  25. Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and non-human primate models

    Article • Nature Communications, March 2024, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  26. A pan-orthohantavirus preclinical human lung xenograft mouse model

    Article • March 2024, Research Square

    Professor (Associate) Bart L. Haagmans

  27. Presence of procoagulant peripheral blood mononuclear cells in severe COVID-19 patients relate to ventilation perfusion mismatch and precede pulmonary embolism

    Article • Journal of Critical Care, February 2024, Elsevier

    Professor (Associate) Bart L. Haagmans

  28. Human metapneumovirus infection of organoid-derived human bronchial epithelium represents cell tropism and cytopathology as observed in in vivo models

    Article • mSphere, January 2024, ASM Journals

    Professor (Associate) Bart L. Haagmans

  29. Identification of a Spike-Specific CD8+ T-Cell Epitope Following Vaccination Against the Middle East Respiratory Syndrome Coronavirus in Humans

    Article • The Journal of Infectious Diseases, January 2024, Oxford University Press (OUP)

    Professor (Associate) Bart L. Haagmans

  30. Human conjunctiva organoids to study ocular surface homeostasis and disease

    Article • Cell Stem Cell, January 2024, Elsevier

    Professor (Associate) Bart L. Haagmans

  31. The Safety, Immunogenicity, and Optimal Dosing of an MVA-Based Vaccine Against MERS Coronavirus in Healthy Adults: A Phase 1b, Randomised, Placebo-Controlled, Double-Blind Clinical Trial

    Article • January 2024, Elsevier

    Professor (Associate) Bart L. Haagmans

  32. Direct comparison of SARS-CoV-2 variant specific neutralizing antibodies in human and hamster sera

    Article • December 2023, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  33. Transient Autoreactive PF4 and Antiphospholipid Antibodies in COVID-19 Vaccine Recipients

    Article • Vaccines, December 2023, MDPI AG

    Professor (Associate) Bart L. Haagmans

  34. Fangchinoline inhibits SARS-CoV-2 and MERS-CoV entry

    Article • Antiviral Research, November 2023, Elsevier

    Professor (Associate) Bart L. Haagmans

  35. Comparative Pathogenesis of Severe Acute Respiratory Syndrome Coronaviruses

    Article • Annual Review of Pathology Mechanisms of Disease, October 2023, Annual Reviews

    Professor (Associate) Bart L. Haagmans

  36. Antigenic evolution of SARS coronavirus 2

    Article • Current Opinion in Virology, October 2023, Elsevier

    Professor (Associate) Bart L. Haagmans

  37. The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses

    Article • Clinical Immunology, October 2023, Elsevier

    Professor (Associate) Bart L. Haagmans

  38. Comparative Analysis of SARS-CoV-2 Antigenicity across Assays and in Human and Animal Model Sera

    Article • September 2023, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  39. SARS-CoV-2 ORF8 accessory protein is a virulence factor

    Article • mBio, August 2023, ASM Journals

    Professor (Associate) Bart L. Haagmans

  40. Distinct COVID-19 vaccine combinations result in divergent immune responses

    Article • August 2023, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans, Douwe Postma

  41. Glycosylated extracellular mucin domains protect against SARS-CoV-2 infection at the respiratory surface

    Article • PLoS Pathogens, August 2023, PLOS

    Professor (Associate) Bart L. Haagmans, Karin Strijbis

  42. SARS-CoV-2 Omicron entry is type II transmembrane serine protease-mediated in human airway and intestinal organoid models

    Article • Journal of Virology, August 2023, ASM Journals

    Professor (Associate) Bart L. Haagmans

  43. Filamentous Fungus-Produced Human Monoclonal Antibody Provides SARS-CoV-2 Protection in Hamster and Non-Human Primate Models

    Article • June 2023, Research Square

    Professor (Associate) Bart L. Haagmans

  44. Preclinical immunogenicity and protective efficacy of a SARS-CoV-2 RBD-based vaccine produced with the thermophilic filamentous fungal expression system Thermothelomyces heterothallica C1

    Article • Frontiers in Immunology, June 2023, Frontiers

    Professor (Associate) Bart L. Haagmans

  45. Correction for Mols et al., “Intestinal Tropism of a Betacoronavirus ( Merbecovirus ) in Nathusius’s Pipistrelle Bat (Pipistrellus nathusii), Its Natural Host”

    Article • Journal of Virology, May 2023, ASM Journals

    Professor (Associate) Bart L. Haagmans

  46. Detection of double-stranded RNA intermediates of four major SARS-CoV-2 variants in formalin-fixed paraffin-embedded lung tissue of Syrian golden hamsters using monoclonal antibodies

    Article • Journal of Comparative Pathology, May 2023, Elsevier

    Professor (Associate) Bart L. Haagmans

  47. SARS-CoV-2 (B1.1.529) Omicron variant: what has changed in the nose?

    Article • Journal of Comparative Pathology, May 2023, Elsevier

    Professor (Associate) Bart L. Haagmans

  48. ICTV Virus Taxonomy Profile: Coronaviridae 2023

    Article • Journal of General Virology, April 2023, Society for General Microbiology

    Professor (Associate) Bart L. Haagmans

  49. The pro-inflammatory response to influenza A virus infection is fueled by endothelial cells

    Article • Life Science Alliance, April 2023, Life Science Alliance, LLC

    Professor (Associate) Bart L. Haagmans

  50. Mpox Virus Impact on Kidney Organoids and Antiviral Treatment Response

    Article • Cell Discovery, April 2023, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  51. Preclinical immunogenicity and protective efficacy of a SARS-CoV-2 RBD based vaccine produced with the thermophilic filamentous fungal expression system Thermothelomyces heterothallica, C1.

    Article • March 2023, Research Square

    Professor (Associate) Bart L. Haagmans

  52. Extended Viral Shedding of MERS-CoV Clade B Virus in Llamas Compared with African Clade C Strain

    Article • Emerging Infectious Diseases, March 2023, Centers for Disease Control and Prevention (CDC)

    Professor (Associate) Bart L. Haagmans

  53. Intestinal Tropism of a Betacoronavirus ( Merbecovirus ) in Nathusius’s Pipistrelle Bat ( Pipistrellus nathusii ), Its Natural Host

    Article • Journal of Virology, March 2023, ASM Journals

    Professor (Associate) Bart L. Haagmans, Vera Mols

  54. Brief Report: Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Subjects Vaccinated with Modified Vaccinia Virus Ankara Encoding MERS-Coronavirus Spike Protein

    Article • The Journal of Infectious Diseases, March 2023, Oxford University Press (OUP)

    Professor (Associate) Bart L. Haagmans

  55. Avidity engineering of human heavy-chain-only antibodies mitigates neutralization resistance of SARS-CoV-2 variants

    Article • Frontiers in Immunology, February 2023, Frontiers

    Professor (Associate) Bart L. Haagmans

  56. Reduced Seasonal Coronavirus Antibody Responses in Children Following COVID-19 Mitigation Measures, The Netherlands

    Article • Viruses, January 2023, MDPI AG

    Professor (Associate) Bart L. Haagmans

  57. Antigenic mapping of emerging SARS-CoV-2 omicron variants BM.1.1.1, BQ.1.1, and XBB.1

    Article • The Lancet Microbe, January 2023, Elsevier

    Professor (Associate) Bart L. Haagmans

  58. Low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals

    Article • Nature Reports Stem Cells, October 2022, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  59. Low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals

    Article • September 2022, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  60. The pro-inflammatory response to influenza A virus infection is fueled by endothelial cells

    Article • August 2022, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  61. Outpatient convalescent plasma therapy for high-risk patients with early COVID-19. A randomized placebo-controlled trial

    Article • Clinical Microbiology and Infection, August 2022, Elsevier

    Professor (Associate) Bart L. Haagmans, Douwe Postma

  62. Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome

    Article • Nature Communications, July 2022, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  63. Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters

    Article • Emerging Microbes & Infections, July 2022, Taylor & Francis

    Professor (Associate) Bart L. Haagmans

  64. Recapitulating infection, thermal sensitivity and antiviral treatment of seasonal coronaviruses in human airway organoids

    Article • EBioMedicine, July 2022, Elsevier

    Professor (Associate) Bart L. Haagmans

  65. Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine

    Article • Cell Reports Medicine, July 2022, Elsevier

    Professor (Associate) Bart L. Haagmans

  66. Protective efficacy of an RBD-based Middle East respiratory syndrome coronavirus (MERS-CoV) particle vaccine in llamas

    Article • One Health Outlook, June 2022, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  67. Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct

    Article • Science Immunology, June 2022, American Association for the Advancement of Science

    Professor (Associate) Bart L. Haagmans

  68. SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of hamsters

    Article • Nature Communications, June 2022, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  69. Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern

    Article • mBio, June 2022, ASM Journals

    Professor (Associate) Bart L. Haagmans

  70. An early warning system for emerging SARS-CoV-2 variants

    Article • Nature Reports Stem Cells, May 2022, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  71. Review 1: "Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets"

    Article • May 2022, The MIT Press

    Professor (Associate) Bart L. Haagmans

  72. An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern

    Article • Science Immunology, April 2022, American Association for the Advancement of Science

    Professor (Associate) Bart L. Haagmans

  73. Methods for fighting emerging pathogens

    Article • Nature Chemical Biology, April 2022, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  74. Defining the risk of SARS-CoV-2 variants on immune protection

    Article • Nature, March 2022, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans, Dr. Louis-Marie Bloyet

  75. SARS-CoV-2 pathogenesis

    Article • Nature Reviews Microbiology, March 2022, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  76. Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters

    Article • March 2022, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  77. The glycosylated extracellular domain of MUC1 protects against SARS-CoV-2 infection at the respiratory surface

    Article • March 2022, European Respiratory Society (ERS)

    Professor (Associate) Bart L. Haagmans

  78. Distinct spatial arrangements of ACE2 and TMPRSS2 expression in Syrian hamster lung lobes dictates SARS-CoV-2 infection patterns

    Article • PLoS Pathogens, March 2022, PLOS

    Professor (Associate) Bart L. Haagmans

  79. Spreading of SARS-CoV-2 from hamsters to humans

    Article • The Lancet, March 2022, Elsevier

    Professor (Associate) Bart L. Haagmans

  80. Omicron BA.1 and BA.2 are antigenically distinct SARS-CoV-2 variants

    Article • February 2022, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  81. An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants

    Article • February 2022, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  82. Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome

    Article • February 2022, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  83. Modeling Infection and Tropism of Human Parainfluenza Virus Type 3 in Ferrets

    Article • mBio, February 2022, ASM Journals

    Professor (Associate) Bart L. Haagmans

  84. Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients

    Article • Science Immunology, February 2022, American Association for the Advancement of Science

    Professor (Associate) Bart L. Haagmans

  85. SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of Syrian golden hamsters (Mesocricetus auratus)

    Article • February 2022, Research Square

    Professor (Associate) Bart L. Haagmans

  86. SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination

    Article • BDJ, January 2022, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  87. SARS-CoV-2 Omicron efficiently infects human airway, but not alveolar epithelium

    Article • January 2022, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  88. Middle East respiratory syndrome coronavirus infection in camelids

    Article • Veterinary Pathology, January 2022, SAGE Publications

    Professor (Associate) Bart L. Haagmans

  89. Divergent SARS CoV-2 Omicron-specific T- and B-cell responses in COVID-19 vaccine recipients

    Article • December 2021, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  90. Experimental and field investigations of exposure, replication and transmission of SARS-CoV-2 in pigs in the Netherlands

    Article • Emerging Microbes & Infections, November 2021, Taylor & Francis

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  91. Interferon-α2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19

    Article • Journal of Clinical Immunology, November 2021, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  92. Targeted proteomics as a tool to detect SARS-CoV-2 proteins in clinical specimens

    Article • PLOS One, November 2021, PLOS

    Professor (Associate) Bart L. Haagmans

  93. Zoonoses Anticipation and Preparedness Initiative, stakeholders conference, February 4 & 5, 2021

    Article • Biologicals, November 2021, Elsevier

    Professor (Associate) Bart L. Haagmans

  94. The glycosylated extracellular domain of MUC1 protects against SARS-CoV-2 infection at the respiratory surface

    Article • October 2021, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans, Karin Strijbis

  95. Author Correction: The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology

    Article • Nature Reports Stem Cells, October 2021, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  96. A CRISPR/Cas9 genetically engineered organoid biobank reveals essential host factors for coronaviruses

    Article • Nature Communications, September 2021, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  97. The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology

    Article • Nature Reports Stem Cells, September 2021, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  98. Seasonal coronavirus-specific B-cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19 patients

    Article • Journal of Clinical Investigation, September 2021, American Society for Clinical Investigation

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  99. The Post-Acute Phase of SARS-CoV-2 Infection in Two Macaque Species Is Associated with Signs of Ongoing Virus Replication and Pathology in Pulmonary and Extrapulmonary Tissues

    Article • Viruses, August 2021, MDPI AG

    Professor (Associate) Bart L. Haagmans

  100. Virological characteristics of SARS-CoV-2 vaccine breakthrough infections in health care workers

    Article • August 2021, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  101. Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test

    Article • One Health, August 2021, Elsevier

    Professor (Associate) Bart L. Haagmans

  102. Interferon-α Auto-Antibodies in Convalescent Plasma Therapy for COVID-19

    Article • July 2021, Research Square

    Professor (Associate) Bart L. Haagmans

  103. Science, not speculation, is essential to determine how SARS-CoV-2 reached humans

    Article • The Lancet, July 2021, Elsevier

    Professor (Associate) Bart L. Haagmans

  104. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination

    Article • Proceedings of the National Academy of Sciences, June 2021, Proceedings of the National Academy of Sciences

    Gerd Sutter, Professor (Associate) Bart L. Haagmans, Nisreen Okba

  105. Animal models of SARS-CoV-2 transmission

    Article • Current Opinion in Virology, June 2021, Elsevier

    Professor (Associate) Bart L. Haagmans

  106. Advancing lung organoids for COVID-19 research

    Article • Disease Models & Mechanisms, June 2021, The Company of Biologists

    Professor (Associate) Bart L. Haagmans

  107. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection

    Article • Nature Communications, May 2021, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  108. SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model

    Article • The Journal of Infectious Diseases, May 2021, Oxford University Press (OUP)

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  109. SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees

    Article • Science Immunology, May 2021, American Association for the Advancement of Science

    Professor (Associate) Bart L. Haagmans, Gerco den Hartog

  110. A CRISPR/Cas9 genetically engineered organoid biobank reveals essential host factors for coronaviruses

    Article • May 2021, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  111. Human Respiratory Syncytial Virus Subgroup A and B Infections in Nasal, Bronchial, Small-Airway, and Organoid-Derived Respiratory Cultures

    Article • mSphere, May 2021, ASM Journals

    Professor (Associate) Bart L. Haagmans

  112. Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test

    Article • May 2021, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  113. The BNT162b2 mRNA vaccine against SARS-CoV-2 reprograms both adaptive and innate immune responses

    Article • May 2021, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  114. Human organoid systems reveal in vitro correlates of fitness for SARS-CoV-2 B.1.1.7

    Article • May 2021, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  115. High Levels of Neutrophil Extracellular Traps Persist in the Lower Respiratory Tract of Critically Ill Patients With Coronavirus Disease 2019

    Article • The Journal of Infectious Diseases, May 2021, Oxford University Press (OUP)

    Professor (Associate) Bart L. Haagmans

  116. Human airway cells prevent SARS-CoV-2 multibasic cleavage site cell culture adaptation

    Article • eLife, April 2021, eLife

    Professor (Associate) Bart L. Haagmans

  117. Author response: Human airway cells prevent SARS-CoV-2 multibasic cleavage site cell culture adaptation

    Article • March 2021, eLife

    Professor (Associate) Bart L. Haagmans

  118. A Single Subcutaneous or Intranasal Immunization with Adenovirus‐Based SARS‐CoV‐2 Vaccine Induces Robust Humoral and Cellular Immune Responses in Mice

    Article • European Journal of Immunology, March 2021, Wiley

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  119. 3D visualization of SARS-CoV-2 infection and receptor distribution in Syrian hamster lung lobes display distinct spatial arrangements

    Article • March 2021, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  120. A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies

    Article • Nature Communications, March 2021, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  121. Review for "A Single Subcutaneous or Intranasal Immunization with Adenovirus‐Based SARS‐CoV‐2 Vaccine Induces Robust Humoral and Cellular Immune Responses in Mice"

    Article • March 2021, Wiley

    Professor (Associate) Bart L. Haagmans

  122. Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets

    Article • Science, February 2021, American Association for the Advancement of Science

    Professor (Associate) Bart L. Haagmans

  123. Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins

    Article • PLoS Pathogens, February 2021, PLOS

    Professor (Associate) Bart L. Haagmans

  124. Neutrophil extracellular traps persist at high levels in the lower respiratory tract of critically ill COVID-19 patients

    Article • The Journal of Infectious Diseases, January 2021, Oxford University Press (OUP)

    Professor (Associate) Bart L. Haagmans

  125. Human airway cells prevent SARS-CoV-2 multibasic cleavage site cell culture adaptation

    Article • January 2021, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  126. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)

    Article • Nature Communications, January 2021, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  127. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vaccination

    Article • January 2021, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  128. SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site

    Article • eLife, January 2021, eLife

    Professor (Associate) Bart L. Haagmans

  129. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection

    Article • Cell, January 2021, Elsevier

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  130. Extended Shedding and Enhanced Fitness of the SARS-CoV-2 Variant of Concern B.1.1.7 in Human Organoid Systems

    Article • SSRN Electronic Journal, January 2021, Elsevier

    Professor (Associate) Bart L. Haagmans

  131. The BNT162b2 mRNA Vaccine Against SARS-CoV-2 Reprograms Both Adaptive and Innate Immune Responses

    Article • SSRN Electronic Journal, January 2021, Elsevier

    Professor (Associate) Bart L. Haagmans

  132. Susceptibility of rabbits to SARS-CoV-2

    Article • Emerging Microbes & Infections, December 2020, Taylor & Francis

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  133. Author response: SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site

    Article • December 2020, eLife

    Professor (Associate) Bart L. Haagmans

  134. Decision letter: SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site

    Article • December 2020, eLife

    Professor (Associate) Bart L. Haagmans

  135. An Organoid‐derived Bronchioalveolar Model for SARS‐CoV‐2 Infection of Human Alveolar‐type II‐like Cells

    Article • The EMBO Journal, December 2020, EMBO

    Professor (Associate) Bart L. Haagmans

  136. Development of immunohistochemistry and in situ hybridisation for the detection of SARS-CoV and SARS-CoV-2 in formalin-fixed paraffin-embedded specimens

    Article • Scientific Reports, December 2020, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans, Professor Nigel James Temperton

  137. Effects of Potent Neutralizing Antibodies from Convalescent Plasma in Patients Hospitalized for Severe SARS-CoV-2 Infection.

    Article • November 2020, Research Square

    Professor (Associate) Bart L. Haagmans

  138. The Importance of Biobanking for Response to Pandemics Caused by Emerging Viruses: The European Virus Archive As an Observatory of the Global Response to the Zika Virus and COVID-19 Crisis

    Article • Biopreservation and Biobanking, November 2020, Mary Ann Liebert Inc

    Professor (Associate) Bart L. Haagmans

  139. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection

    Article • November 2020, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  140. Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets

    Article • November 2020, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  141. Comparison of SARS-CoV-2 infection in two non-human primate species: rhesus and cynomolgus macaques

    Article • November 2020, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  142. How the COVID-19 pandemic highlights the necessity of animal research

    Article • Current Biology, November 2020, Elsevier

    Professor (Associate) Bart L. Haagmans, Andries Kalsbeek, Senior scientist Laila Ritsma

  143. Isolation of cross-reactive monoclonal antibodies against divergent human coronaviruses that delineate a conserved and vulnerable site on the spike protein

    Article • October 2020, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  144. Severe COVID-19 patients display a back boost of seasonal coronavirus-specific antibodies

    Article • October 2020, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  145. Animal models for COVID-19

    Article • Nature, September 2020, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans, Dr Randy A Albrecht, Dr Jens H. Kuhn

  146. The SARS-CoV-2 multibasic cleavage site facilitates early serine protease-mediated entry into organoid-derived human airway cells

    Article • September 2020, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  147. Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins

    Article • September 2020, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  148. Susceptibility of rabbits to SARS-CoV-2

    Article • August 2020, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  149. Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands

    Article • August 2020, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  150. SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model

    Article • August 2020, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  151. How the COVID-19 pandemic highlights the necessity of animal research

    Article • Current Biology, August 2020, Elsevier

    Professor (Associate) Bart L. Haagmans

  152. Assessing the extent of SARS-CoV-2 circulation through serological studies

    Article • Nature Reports Stem Cells, July 2020, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  153. SARS-CoV-2 is transmitted via contact and via the air between ferrets

    Article • Nature Communications, July 2020, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  154. An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment

    Article • Nature Communications, July 2020, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  155. Convalescent Plasma for COVID-19. A randomized clinical trial

    Article • July 2020, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  156. Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease 2019 Patients

    Article • Emerging Infectious Diseases, July 2020, Centers for Disease Control and Prevention (CDC)

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  157. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome

    Article • Science Immunology, June 2020, American Association for the Advancement of Science

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  158. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

    Article • Science, June 2020, American Association for the Advancement of Science

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  159. Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants

    Article • June 2020, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  160. Publisher Correction: A human monoclonal antibody blocking SARS-CoV-2 infection

    Article • Nature Communications, May 2020, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  161. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

    Article • May 2020, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  162. A human monoclonal antibody blocking SARS-CoV-2 infection

    Article • Nature Communications, May 2020, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  163. Serologic Detection of Middle East Respiratory Syndrome Coronavirus Functional Antibodies

    Article • Emerging Infectious Diseases, May 2020, Centers for Disease Control and Prevention (CDC)

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  164. SARS-CoV-2 productively infects human gut enterocytes

    Article • Science, May 2020, American Association for the Advancement of Science

    Professor (Associate) Bart L. Haagmans

  165. Towards the next phase: evaluation of serological assays for diagnostics and exposure assessment.

    Article • April 2020, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  166. SARS-CoV-2 Productively Infects Human Gut Enterocytes

    Article • April 2020, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  167. Targeted Proteomics for the Detection of SARS-CoV-2 Proteins

    Article • April 2020, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  168. Phenotype of SARS-CoV-2-specific T-cells in COVID-19 patients with acute respiratory distress syndrome

    Article • April 2020, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  169. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model

    Article • Science, April 2020, American Association for the Advancement of Science

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  170. SARS-CoV-2 is transmitted via contact and via the air between ferrets.

    Article • April 2020, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  171. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Seropositive Camel Handlers in Kenya

    Article • Viruses, April 2020, MDPI AG

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  172. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development

    Article • EBioMedicine, April 2020, Elsevier

    Professor (Associate) Bart L. Haagmans

  173. Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial

    Article • The Lancet Infectious Diseases, April 2020, Elsevier

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  174. SARS-CoV-2 specific antibody responses in COVID-19 patients

    Article • March 2020, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  175. Comparative Pathogenesis Of COVID-19, MERS And SARS In A Non-Human Primate Model

    Article • March 2020, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  176. A human monoclonal antibody blocking SARS-CoV-2 infection

    Article • March 2020, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  177. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

    Article • Nature Microbiology, March 2020, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  178. Authors’ response: Plenty of coronaviruses but no SARS-CoV-2

    Article • Eurosurveillance, February 2020, European Centre for Disease Control and Prevention (ECDC)

    Professor (Associate) Bart L. Haagmans

  179. Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries, January 2020

    Article • Eurosurveillance, February 2020, European Centre for Disease Control and Prevention (ECDC)

    Professor (Associate) Bart L. Haagmans

  180. Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group

    Article • February 2020, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  181. Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19

    Article • The Lancet, February 2020, Elsevier

    Professor (Associate) Bart L. Haagmans

  182. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

    Article • Eurosurveillance, January 2020, European Centre for Disease Control and Prevention (ECDC)

    Professor (Associate) Bart L. Haagmans

  183. Note from the editors: novel coronavirus (2019-nCoV)

    Article • Eurosurveillance, January 2020, European Centre for Disease Control and Prevention (ECDC)

    Professor (Associate) Bart L. Haagmans

  184. Particulate multivalent presentation of the receptor binding domain induces protective immune responses against MERS-CoV

    Article • Emerging Microbes & Infections, January 2020, Taylor & Francis

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  185. Two-Component Spike Nanoparticle Vaccine Protects Macaques from SARS-CoV-2 Infection

    Article • SSRN Electronic Journal, January 2020, Elsevier

    Professor (Associate) Bart L. Haagmans

  186. MERS-CoV in Camels but Not Camel Handlers, Sudan, 2015 and 2017

    Article • Emerging Infectious Diseases, December 2019, Centers for Disease Control and Prevention (CDC)

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  187. Machine-learning based patient classification using Hepatitis B virus full-length genome quasispecies from Asian and European cohorts

    Article • Scientific Reports, December 2019, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  188. Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections

    Article • Emerging Infectious Diseases, October 2019, Centers for Disease Control and Prevention (CDC)

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  189. Comparison of Serologic Assays for Middle East Respiratory Syndrome Coronavirus

    Article • Emerging Infectious Diseases, October 2019, Centers for Disease Control and Prevention (CDC)

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  190. ADAR1: “Editor-in-Chief” of Cytoplasmic Innate Immunity

    Article • Frontiers in Immunology, July 2019, Frontiers

    Professor (Associate) Bart L. Haagmans

  191. Failure to detect MERS‐CoV RNA in urine of naturally infected dromedary camels

    Article • Zoonoses and Public Health, July 2019, Wiley

    Professor (Associate) Bart L. Haagmans

  192. Species-Specific Colocalization of Middle East Respiratory Syndrome Coronavirus Attachment and Entry Receptors

    Article • Journal of Virology, June 2019, ASM Journals

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  193. Lack of Middle East Respiratory Syndrome Coronavirus Transmission in Rabbits

    Article • Viruses, April 2019, MDPI AG

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  194. Host Determinants of MERS-CoV Transmission and Pathogenesis

    Article • Viruses, March 2019, MDPI AG

    Professor (Associate) Bart L. Haagmans

  195. Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein

    Article • Emerging Microbes & Infections, January 2019, Taylor & Francis

    Professor (Associate) Bart L. Haagmans, Nisreen Okba, Stalin Raj VICTOR, Francisco Javier Gutierrez Alvarez, Yiping Rong

  196. Blocking transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) in llamas by vaccination with a recombinant spike protein

    Article • Emerging Microbes & Infections, January 2019, Taylor & Francis

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  197. Co-localization of Middle East respiratory syndrome coronavirus (MERS-CoV) and dipeptidyl peptidase-4 in the respiratory tract and lymphoid tissues of pigs and llamas

    Article • Transboundary and Emerging Diseases, December 2018, Wiley

    Professor (Associate) Bart L. Haagmans

  198. Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection

    Article • Science Advances, August 2018, American Association for the Advancement of Science

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  199. Experimental infection of dromedaries with Middle East respiratory syndrome-Coronavirus is accompanied by massive ciliary loss and depletion of the cell surface receptor dipeptidyl peptidase 4

    Article • Scientific Reports, June 2018, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  200. Middle East respiratory syndrome coronavirus specific antibodies in naturally exposed Israeli llamas, alpacas and camels

    Article • One Health, May 2018, Elsevier

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  201. Multi-hospital outbreak of a Middle East respiratory syndrome coronavirus deletion variant, Jordan: A molecular, serologic, and epidemiologic investigation

    Article • Open Forum Infectious Diseases, April 2018, Oxford University Press (OUP)

    Professor (Associate) Bart L. Haagmans

  202. Tissue Distribution of the Mers-Coronavirus Receptor in Bats

    Article • Journal of Comparative Pathology, January 2018, Elsevier

    Professor (Associate) Bart L. Haagmans

  203. Cell Tropism of Middle East Respiratory Syndrome Coronavirus in Experimentally Infected Dromedaries

    Article • Journal of Comparative Pathology, January 2018, Elsevier

    Professor (Associate) Bart L. Haagmans

  204. Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein

    Article • Proceedings of the National Academy of Sciences, September 2017, Proceedings of the National Academy of Sciences

    Professor (Associate) Bart L. Haagmans

  205. DPP4, the Middle East Respiratory Syndrome Coronavirus Receptor, is Upregulated in Lungs of Smokers and Chronic Obstructive Pulmonary Disease Patients

    Article • Clinical Infectious Diseases, August 2017, Oxford University Press (OUP)

    Professor (Associate) Bart L. Haagmans

  206. Phenotypic Differences between Asian and African Lineage Zika Viruses in Human Neural Progenitor Cells

    Article • mSphere, July 2017, ASM Journals

    Professor (Associate) Bart L. Haagmans

  207. Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve Patients

    Article • Scientific Reports, July 2017, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans, Dr Gadissa Bedada Hundie

  208. Middle East respiratory syndrome coronavirus experimental transmission using a pig model

    Article • Transboundary and Emerging Diseases, June 2017, Wiley

    Professor (Associate) Bart L. Haagmans

  209. MERS-coronavirus: From discovery to intervention

    Article • One Health, June 2017, Elsevier

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  210. Genetic diversity of hepatitis C virus in Ethiopia

    Article • PLOS One, June 2017, PLOS

    Professor (Associate) Bart L. Haagmans, Dr Gadissa Bedada Hundie

  211. Tissue Distribution of the MERS-Coronavirus Receptor in Bats

    Article • Scientific Reports, April 2017, Nature

    Professor (Associate) Bart L. Haagmans

  212. Virus genomes reveal factors that spread and sustained the Ebola epidemic

    Article • Nature, April 2017, Nature

    Professor (Associate) Bart L. Haagmans, Dr Armando Arias, Dr Jens H. Kuhn

  213. Risk Factors for Primary Middle East Respiratory Syndrome Coronavirus Infection in Camel Workers in Qatar During 2013–2014: A Case-Control Study

    Article • The Journal of Infectious Diseases, April 2017, Oxford University Press (OUP)

    Professor (Associate) Bart L. Haagmans

  214. Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches

    Article • Current Opinion in Virology, April 2017, Elsevier

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  215. Seroepidemiology of hepatitis B and C virus infections among blood donors in Ethiopia

    Article • Journal of Medical Virology, February 2017, Wiley

    Professor (Associate) Bart L. Haagmans, Dr Gadissa Bedada Hundie

  216. Livestock Susceptibility to Infection with Middle East Respiratory Syndrome Coronavirus

    Article • Emerging Infectious Diseases, February 2017, Centers for Disease Control and Prevention (CDC)

    Professor (Associate) Bart L. Haagmans

  217. Respiratory Infection Routes of MERS-CoV in Rabbits

    Article • Journal of Comparative Pathology, January 2017, Elsevier

    Professor (Associate) Bart L. Haagmans

  218. Development of Different Animal Models for Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) Infection

    Article • Journal of Comparative Pathology, January 2017, Elsevier

    Professor (Associate) Bart L. Haagmans

  219. The sample of choice for detecting Middle East respiratory syndrome coronavirus in asymptomatic dromedary camels using real-time reversetranscription polymerase chain reaction

    Article • Revue Scientifique et Technique de l OIE, December 2016, O.I.E (World Organisation for Animal Health)

    Professor (Associate) Bart L. Haagmans

  220. A novel hepatitis B virus subgenotype D10 circulating in Ethiopia

    Article • Journal of Viral Hepatitis, November 2016, Wiley

    Professor (Associate) Bart L. Haagmans, Dr Gadissa Bedada Hundie

  221. Miscarriage Associated with Zika Virus Infection

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, September 2016, New England Journal of Medicine (NEJM/MMS)

    Professor (Associate) Bart L. Haagmans

  222. Virus genomes reveal the factors that spread and sustained the West African Ebola epidemic.

    Article • September 2016, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans

  223. Naturally occurring recombination in ferret coronaviruses revealed by complete genome characterization

    Article • Journal of General Virology, September 2016, Society for General Microbiology

    Professor (Associate) Bart L. Haagmans, Dr Gadissa Bedada Hundie

  224. Toward Developing a Preventive MERS-CoV Vaccine—Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14–15, 2015

    Article • Emerging Infectious Diseases, August 2016, Centers for Disease Control and Prevention (CDC)

    Professor (Associate) Bart L. Haagmans

  225. MERS-CoV Infection of Alpaca in a Region Where MERS-CoV is Endemic

    Article • Emerging Infectious Diseases, June 2016, Centers for Disease Control and Prevention (CDC)

    Professor (Associate) Bart L. Haagmans

  226. Deletion Variants of Middle East Respiratory Syndrome Coronavirus from Humans, Jordan, 2015

    Article • Emerging Infectious Diseases, April 2016, Centers for Disease Control and Prevention (CDC)

    Professor (Associate) Bart L. Haagmans

  227. A poxvirus-based vaccine reduces virus excretion after MERS coronavirus infection in dromedary camels

    Article • International Journal of Infectious Diseases, April 2016, Elsevier

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  228. Hepatitis E Virus (HEV) Genotype 3 Infection of Human Liver Chimeric Mice as a Model for Chronic HEV Infection

    Article • Journal of Virology, February 2016, ASM Journals

    Professor (Associate) Bart L. Haagmans

  229. Differential Expression of the Middle East Respiratory Syndrome Coronavirus Receptor in the Upper Respiratory Tracts of Humans and Dromedary Camels

    Article • Journal of Virology, February 2016, ASM Journals

    Professor (Associate) Bart L. Haagmans

  230. Cross host transmission in the emergence of MERS coronavirus

    Article • Current Opinion in Virology, February 2016, Elsevier

    Professor (Associate) Bart L. Haagmans

  231. Mers Coronavirus Infection in Dromedary Camels

    Article • Journal of Comparative Pathology, January 2016, Elsevier

    Professor (Associate) Bart L. Haagmans

  232. Ebola virus laboratory response: the three Dutch Mobile laboratories in Liberia and Sierra Leone

    Article • Clinical Microbiology and Infectious Diseases, January 2016, Open Access Text Pvt, Ltd.

    Professor (Associate) Bart L. Haagmans

  233. Molecular epidemiology and genetic diversity of hepatitis B virus in Ethiopia

    Article • Journal of Medical Virology, December 2015, Wiley

    Professor (Associate) Bart L. Haagmans, Dr Gadissa Bedada Hundie

  234. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels

    Article • Science, December 2015, American Association for the Advancement of Science

    Professor (Associate) Bart L. Haagmans, Nisreen Okba

  235. Intrathecal CD4+and CD8+T-cell responses to endogenously synthesized candidate disease-associated human autoantigens in multiple sclerosis patients

    Article • European Journal of Immunology, November 2015, Wiley

    Professor (Associate) Bart L. Haagmans

  236. Genotypic anomaly in Ebola virus strains circulating in Magazine Wharf area, Freetown, Sierra Leone, 2015

    Article • Eurosurveillance, October 2015, European Centre for Disease Control and Prevention (ECDC)

    Professor (Associate) Bart L. Haagmans, Dr Armando Arias

  237. Deployment of Dutch mobile laboratories in the West African Ebola virus response

    Article • Journal of Clinical Virology, September 2015, Elsevier

    Professor (Associate) Bart L. Haagmans

  238. Follow-up of Contacts of Middle East Respiratory Syndrome Coronavirus–Infected Returning Travelers, the Netherlands, 2014

    Article • Emerging Infectious Diseases, September 2015, Centers for Disease Control and Prevention (CDC)

    Professor (Associate) Bart L. Haagmans

  239. Novel in vivo and in vitro models of Hepatitis E virus genotype 3 infectivity for chronic human HEV infection

    Article • Journal of Clinical Virology, September 2015, Elsevier

    Professor (Associate) Bart L. Haagmans

  240. Occupational Exposure to Dromedaries and Risk for MERS-CoV Infection, Qatar, 2013–2014

    Article • Emerging Infectious Diseases, August 2015, Centers for Disease Control and Prevention (CDC)

    Professor (Associate) Bart L. Haagmans

  241. Detection of Circovirus in Foxes with Meningoencephalitis, United Kingdom, 2009–2013

    Article • Emerging Infectious Diseases, July 2015, Centers for Disease Control and Prevention (CDC)

    Professor (Associate) Bart L. Haagmans

  242. Asymptomatic Middle East Respiratory Syndrome Coronavirus Infection in Rabbits

    Article • Journal of Virology, March 2015, ASM Journals

    Professor (Associate) Bart L. Haagmans

  243. Reliable typing of MERS-CoV variants with a small genome fragment

    Article • Journal of Clinical Virology, March 2015, Elsevier

    Professor (Associate) Bart L. Haagmans

  244. Inflammatory Monocytes Recruited to the Liver within 24 Hours after Virus-Induced Inflammation Resemble Kupffer Cells but Are Functionally Distinct

    Article • Journal of Virology, February 2015, ASM Journals

    Professor (Associate) Bart L. Haagmans

  245. ATP1A1-Mediated Src Signaling Inhibits Coronavirus Entry into Host Cells

    Article • Journal of Virology, February 2015, ASM Journals

    Professor (Associate) Bart L. Haagmans

  246. Genome Sequence of Enterovirus D68 and Clinical Disease, Thailand

    Article • Emerging Infectious Diseases, February 2015, Centers for Disease Control and Prevention (CDC)

    Professor (Associate) Bart L. Haagmans

  247. Identification of Protein Receptors for Coronaviruses by Mass Spectrometry

    Article • January 2015, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  248. Mers coronavirus infection of rabbits

    Article • Journal of Comparative Pathology, January 2015, Elsevier

    Professor (Associate) Bart L. Haagmans

  249. High proportion of MERS-CoV shedding dromedaries at slaughterhouse with a potential epidemiological link to human cases, Qatar 2014

    Article • Infection Ecology & Epidemiology, January 2015, Taylor & Francis

    Professor (Associate) Bart L. Haagmans

  250. Pathogenesis of Middle East respiratory syndrome coronavirus

    Article • The Journal of Pathology, December 2014, Wiley

    Professor (Associate) Bart L. Haagmans

  251. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen

    Article • International Journal of Antimicrobial Agents, December 2014, Elsevier

    Professor (Associate) Bart L. Haagmans

  252. Coronavirus Cell Entry Occurs through the Endo-/Lysosomal Pathway in a Proteolysis-Dependent Manner

    Article • PLoS Pathogens, November 2014, PLOS

    Professor (Associate) Bart L. Haagmans

  253. Travel-related MERS-CoV cases: an assessment of exposures and risk factors in a group of Dutch travellers returning from the Kingdom of Saudi Arabia, May 2014

    Article • Emerging Themes in Epidemiology, October 2014, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  254. Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice

    Article • Vaccine, October 2014, Elsevier

    Professor (Associate) Bart L. Haagmans

  255. Metagenomic Survey for Viruses in Western Arctic Caribou, Alaska, through Iterative Assembly of Taxonomic Units

    Article • PLOS One, August 2014, PLOS

    Professor (Associate) Bart L. Haagmans

  256. Exploring the Potential of Next-Generation Sequencing in Detection of Respiratory Viruses

    Article • Journal of Clinical Microbiology, August 2014, ASM Journals

    Professor (Associate) Bart L. Haagmans

  257. Geographic Distribution of MERS Coronavirus among Dromedary Camels, Africa

    Article • Emerging Infectious Diseases, August 2014, Centers for Disease Control and Prevention (CDC)

    Professor (Associate) Bart L. Haagmans, Professor Lilia Messadi

  258. Isolation of MERS Coronavirus from a Dromedary Camel, Qatar, 2014

    Article • Emerging Infectious Diseases, August 2014, Centers for Disease Control and Prevention (CDC)

    Professor (Associate) Bart L. Haagmans

  259. Novel divergent nidovirus in a python with pneumonia

    Article • Journal of General Virology, July 2014, Society for General Microbiology

    Professor (Associate) Bart L. Haagmans

  260. Geographic Distribution of MERS Coronavirus among Dromedary Camels, Africa

    Article • Emerging Infectious Diseases, July 2014, Centers for Disease Control and Prevention (CDC)

    Professor (Associate) Bart L. Haagmans

  261. New Viruses in Idiopathic Human Diarrhea Cases, the Netherlands

    Article • Emerging Infectious Diseases, July 2014, Centers for Disease Control and Prevention (CDC)

    Professor (Associate) Bart L. Haagmans

  262. The Pathology and Pathogenesis of Experimental Severe Acute Respiratory Syndrome and Influenza in Animal Models

    Article • Journal of Comparative Pathology, July 2014, Elsevier

    Professor (Associate) Bart L. Haagmans

  263. Middle East respiratory syndrome coronavirus (MERS-CoV) RNA and neutralising antibodies in milk collected according to local customs from dromedary camels, Qatar, April 2014

    Article • Eurosurveillance, June 2014, European Centre for Disease Control and Prevention (ECDC)

    Professor (Associate) Bart L. Haagmans

  264. Membrane ectopeptidases targeted by human coronaviruses

    Article • Current Opinion in Virology, June 2014, Elsevier

    Professor (Associate) Bart L. Haagmans

  265. Middle East respiratory syndrome coronavirus (MERS-CoV) infections in two returning travellers in the Netherlands, May 2014

    Article • Eurosurveillance, May 2014, European Centre for Disease Control and Prevention (ECDC)

    Professor (Associate) Bart L. Haagmans

  266. Neutralizing the MERS Coronavirus Threat

    Article • Science Translational Medicine, May 2014, American Association for the Advancement of Science

    Professor (Associate) Bart L. Haagmans

  267. MERS: emergence of a novel human coronavirus

    Article • Current Opinion in Virology, April 2014, Elsevier

    Professor (Associate) Bart L. Haagmans

  268. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation

    Article • The Lancet Infectious Diseases, February 2014, Elsevier

    Professor (Associate) Bart L. Haagmans

  269. Faculty Opinions recommendation of Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation.

    Article • January 2014, F1000Research

    Professor (Associate) Bart L. Haagmans

  270. The Novel Human Coronavirus EMC Causes Disease in Macaques but not in Ferrets

    Article • Journal of Comparative Pathology, January 2014, Elsevier

    Professor (Associate) Bart L. Haagmans

  271. Updated Phylogenetic Analysis of Arenaviruses Detected in Boid Snakes

    Article • Journal of Virology, December 2013, ASM Journals

    Professor (Associate) Bart L. Haagmans

  272. Middle East Respiratory Syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013

    Article • Eurosurveillance, December 2013, European Centre for Disease Control and Prevention (ECDC)

    Professor (Associate) Bart L. Haagmans

  273. Adenosine Deaminase Acts as a Natural Antagonist for Dipeptidyl Peptidase 4-Mediated Entry of the Middle East Respiratory Syndrome Coronavirus

    Article • Journal of Virology, November 2013, ASM Journals

    Professor (Associate) Bart L. Haagmans

  274. Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients

    Article • Journal of Medical Virology, October 2013, Wiley

    Professor (Associate) Bart L. Haagmans

  275. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study

    Article • The Lancet Infectious Diseases, October 2013, Elsevier

    Professor (Associate) Bart L. Haagmans, Christian Gortazar

  276. Inhibition of Middle East Respiratory Syndrome Coronavirus Infection by Anti-CD26 Monoclonal Antibody

    Article • Journal of Virology, September 2013, ASM Journals

    Professor (Associate) Bart L. Haagmans

  277. Novel Cyclovirus in Human Cerebrospinal Fluid, Malawi, 2010–2011

    Article • Emerging Infectious Diseases, September 2013, Centers for Disease Control and Prevention (CDC)

    Professor (Associate) Bart L. Haagmans

  278. Middle East Respiratory Syndrome Coronavirus Spike Protein Delivered by Modified Vaccinia Virus Ankara Efficiently Induces Virus-Neutralizing Antibodies

    Article • Journal of Virology, August 2013, ASM Journals

    Gerd Sutter, Professor (Associate) Bart L. Haagmans

  279. Metagenomic Analysis of the Ferret Fecal Viral Flora

    Article • PLOS One, August 2013, PLOS

    Professor (Associate) Bart L. Haagmans

  280. Spiking the MERS-coronavirus receptor

    Article • BDJ, August 2013, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  281. Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells

    Article • Proceedings of the National Academy of Sciences, July 2013, Proceedings of the National Academy of Sciences

    Professor (Associate) Bart L. Haagmans

  282. Identification and Characterization of Two Novel Viruses in Ocular Infections in Reindeer

    Article • PLOS One, July 2013, PLOS

    Professor (Associate) Bart L. Haagmans

  283. The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Does Not Replicate in Syrian Hamsters

    Article • PLOS One, July 2013, PLOS

    Professor (Associate) Bart L. Haagmans

  284. The Receptor Binding Domain of the New Middle East Respiratory Syndrome Coronavirus Maps to a 231-Residue Region in the Spike Protein That Efficiently Elicits Neutralizing Antibodies

    Article • Journal of Virology, June 2013, ASM Journals

    Professor (Associate) Bart L. Haagmans

  285. T-Cell Tropism of Simian Varicella Virus during Primary Infection

    Article • PLoS Pathogens, May 2013, PLOS

    Professor (Associate) Bart L. Haagmans

  286. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-  treatment

    Article • Journal of General Virology, April 2013, Society for General Microbiology

    Professor (Associate) Bart L. Haagmans

  287. Identification of Multiple Novel Viruses, Including a Parvovirus and a Hepevirus, in Feces of Red Foxes

    Article • Journal of Virology, April 2013, ASM Journals

    Professor (Associate) Bart L. Haagmans

  288. Specific serology for emerging human coronaviruses by protein microarray

    Article • Eurosurveillance, April 2013, European Centre for Disease Control and Prevention (ECDC)

    Professor (Associate) Bart L. Haagmans

  289. Detection of novel divergent arenaviruses in boid snakes with inclusion body disease in The Netherlands

    Article • Journal of General Virology, March 2013, Society for General Microbiology

    Professor (Associate) Bart L. Haagmans

  290. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC

    Article • Nature, March 2013, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  291. Modeling Host Genetic Regulation of Influenza Pathogenesis in the Collaborative Cross

    Article • PLoS Pathogens, February 2013, PLOS

    Professor (Associate) Bart L. Haagmans

  292. Impact of Soluble CD26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection

    Article • PLOS One, February 2013, PLOS

    Professor (Associate) Bart L. Haagmans

  293. Presence of anti-interferon antibodies is not associated with non-response to peginterferon treatment in chronic hepatitis B

    Article • Antiviral Therapy, January 2013, International Medical Press

    Professor (Associate) Bart L. Haagmans

  294. State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Humans

    Article • PLoS Currents, January 2013, PLOS

    Professor (Associate) Bart L. Haagmans

  295. Human Coronavirus EMC Does Not Require the SARS-Coronavirus Receptor and Maintains Broad Replicative Capability in Mammalian Cell Lines

    Article • mBio, December 2012, ASM Journals

    Professor (Associate) Bart L. Haagmans

  296. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections

    Article • Eurosurveillance, December 2012, European Centre for Disease Control and Prevention (ECDC)

    Professor (Associate) Bart L. Haagmans

  297. Genomic Characterization of a Newly Discovered Coronavirus Associated with Acute Respiratory Distress Syndrome in Humans

    Article • mBio, November 2012, ASM Journals

    Professor (Associate) Bart L. Haagmans

  298. Performance Evaluation of the New Roche cobas AmpliPrep/cobas TaqMan HCV Test, Version 2.0, for Detection and Quantification of Hepatitis C Virus RNA

    Article • Journal of Clinical Microbiology, November 2012, ASM Journals

    Professor (Associate) Bart L. Haagmans

  299. Picobirnaviruses in the Human Respiratory Tract

    Article • Emerging Infectious Diseases, September 2012, Centers for Disease Control and Prevention (CDC)

    Professor (Associate) Bart L. Haagmans

  300. Novel Hepatitis E Virus in Ferrets, the Netherlands

    Article • Emerging Infectious Diseases, August 2012, Centers for Disease Control and Prevention (CDC)

    Professor (Associate) Bart L. Haagmans

  301. Calicivirus from Novel Recovirus Genogroup in Human Diarrhea, Bangladesh

    Article • Emerging Infectious Diseases, July 2012, Centers for Disease Control and Prevention (CDC)

    Professor (Associate) Bart L. Haagmans

  302. Impact of Obesity on the Bioavailability of Peginterferon-α2a and Ribavirin and Treatment Outcome for Chronic Hepatitis C Genotype 2 or 3

    Article • PLOS One, May 2012, PLOS

    Professor (Associate) Bart L. Haagmans

  303. Expression Quantitative Trait Loci for Extreme Host Response to Influenza A in Pre-Collaborative Cross Mice

    Article • G3 Genes Genomes Genetics, February 2012, Genetics Society of America

    Professor (Associate) Bart L. Haagmans

  304. Metagenomic Analysis of the Viral Flora of Pine Marten and European Badger Feces

    Article • Journal of Virology, December 2011, ASM Journals

    Professor (Associate) Bart L. Haagmans

  305. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C

    Article • Journal of Hepatology, November 2011, Elsevier

    Professor (Associate) Bart L. Haagmans

  306. Contents

    Article • Journal of Hepatology, November 2011, Elsevier

    Professor (Associate) Bart L. Haagmans

  307. Enteric Coronavirus in Ferrets, the Netherlands

    Article • Emerging Infectious Diseases, August 2011, Centers for Disease Control and Prevention (CDC)

    Professor (Associate) Bart L. Haagmans

  308. Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy

    Article • AIDS, June 2011, Wolters Kluwer Health

    Professor (Associate) Bart L. Haagmans

  309. A Recombinant Influenza A Virus Expressing Domain III of West Nile Virus Induces Protective Immune Responses against Influenza and West Nile Virus

    Article • PLOS One, April 2011, PLOS

    Professor (Associate) Bart L. Haagmans

  310. Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B-Related Single Nucleotide Polymorphisms

    Article • PLOS One, February 2011, PLOS

    Professor (Associate) Bart L. Haagmans

  311. Distinct Severe Acute Respiratory Syndrome Coronavirus-Induced Acute Lung Injury Pathways in Two Different Nonhuman Primate Species

    Article • Journal of Virology, February 2011, ASM Journals

    Professor (Associate) Bart L. Haagmans, Dr ir Wilfred van IJcken

  312. Continuous interferon-α2b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients

    Article • Antiviral Therapy, January 2011, International Medical Press

    Professor (Associate) Bart L. Haagmans

  313. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon–ribavirin combination therapy after 4 weeks of treatment

    Article • European Journal of Gastroenterology & Hepatology, September 2010, Wolters Kluwer Health

    Professor Geert Leroux-Roels, Professor (Associate) Bart L. Haagmans

  314. Pharmacodynamics of PEG-IFN-α-2a in HIV/HCV co-infected patients: Implications for treatment outcomes

    Article • Journal of Hepatology, September 2010, Elsevier

    Professor (Associate) Bart L. Haagmans

  315. 2011 IL28B POLYMORPHISM IS SIGNIFICANTLY CORRELATED WITH IFN ANTI-VIRAL EFFECTIVENESS ALREADY ON FIRST DAY OF PEGYLATED INTERFERON-α AND RIBAVIRIN THERAPY OF CHRONIC HCV INFECTION

    Article • Journal of Hepatology, April 2010, Elsevier

    Professor (Associate) Bart L. Haagmans

  316. Nonresponder Patients with Hepatitis C Virus Genotype 2/3 Infection: A Question of Low Systemic Interferon Concentrations?

    Article • Clinical Infectious Diseases, February 2010, Oxford University Press (OUP)

    Professor (Associate) Bart L. Haagmans

  317. Exacerbated Innate Host Response to SARS-CoV in Aged Non-Human Primates

    Article • PLoS Pathogens, February 2010, PLOS

    Professor (Associate) Bart L. Haagmans, Dr ir Wilfred van IJcken

  318. Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics

    Article • AIDS, November 2009, Wolters Kluwer Health

    Professor (Associate) Bart L. Haagmans

  319. The Application of Genomics to Emerging Zoonotic Viral Diseases

    Article • PLoS Pathogens, October 2009, PLOS

    Professor (Associate) Bart L. Haagmans

  320. Detection and biological activity of therapeutically induced antibodies to peg-IFN-α-2a in hepatitis C virus infected patients

    Article • Cytokine, October 2009, Elsevier

    Professor (Associate) Bart L. Haagmans

  321. Interferon response in murine plasmacytoid dendritic cells after SARS coronavirus infection

    Article • Cytokine, October 2009, Elsevier

    Professor (Associate) Bart L. Haagmans

  322. Early Upregulation of Acute Respiratory Distress Syndrome-Associated Cytokines Promotes Lethal Disease in an Aged-Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Infection

    Article • Journal of Virology, September 2009, ASM Journals

    Professor (Associate) Bart L. Haagmans

  323. Early Upregulation of Acute Respiratory Distress Syndrome-Associated Cytokines Promotes Lethal Disease in an Aged-Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Infection

    Article • Journal of Virology, May 2009, ASM Journals

    Professor (Associate) Bart L. Haagmans

  324. SARS

    Article • January 2009, Elsevier

    Professor (Associate) Bart L. Haagmans

  325. Unraveling the complexities of the interferon response during SARS-CoV infection

    Article • Future Virology, January 2009, Future Medicine

    Professor (Associate) Bart L. Haagmans

  326. Virogenomics: the virus–host interaction revisited

    Article • Current Opinion in Microbiology, October 2008, Elsevier

    Professor (Associate) Bart L. Haagmans

  327. 27 Severe SARS coronavirus infection in aged macaques is associated with reduced expression of anti-inflammatory type-1 interferons

    Article • Cytokine, September 2008, Elsevier

    Professor (Associate) Bart L. Haagmans

  328. DC-SIGN enhances infection of cells with glycosylated West Nile virus in vitro and virus replication in human dendritic cells induces production of IFN-α and TNF-α

    Article • Virus Research, July 2008, Elsevier

    Professor (Associate) Bart L. Haagmans

  329. Pathology of Experimental SARS Coronavirus Infection in Cats and Ferrets

    Article • Veterinary Pathology, July 2008, SAGE Publications

    Professor (Associate) Bart L. Haagmans

  330. Effect of postponed treatment with an anti-tumour necrosis factor (TNF) F(ab')2 fragment on endotoxin-induced cytokine and neutrophil responses in chimpanzees

    Article • Clinical & Experimental Immunology, June 2008, Wiley

    Professor (Associate) Bart L. Haagmans

  331. ALT and viral load decline during PEG-IFN alpha-2b treatment for HBeAg-positive chronic hepatitis B

    Article • Journal of Clinical Virology, June 2008, Elsevier

    Professor (Associate) Bart L. Haagmans

  332. Complete genome analysis of hepatitis C virus subtypes 6t and 6u

    Article • Journal of General Virology, May 2008, Society for General Microbiology

    Professor (Associate) Bart L. Haagmans

  333. Severe acute respiratory syndrome (SARS) vaccines

    Article • January 2008, Elsevier

    Professor (Associate) Bart L. Haagmans

  334. Contributors

    Article • January 2008, Elsevier

    Professor (Associate) Bart L. Haagmans

  335. Modelling of Early Viral Kinetics and Pegylated Interferon-α2b Pharmacokinetics in Patients with HBeAg-Positive Chronic Hepatitis B

    Article • Antiviral Therapy, November 2007, SAGE Publications

    Professor (Associate) Bart L. Haagmans

  336. HCV-Specific T-Cell Response in Relation to Viral Kinetics and Treatment Outcome (DITTO-HCV Project)

    Article • Gastroenterology, October 2007, Elsevier

    Professor (Associate) Bart L. Haagmans

  337. Induction of Regulatory T-Cells and Interleukin-10-Producing Cells in Non-Responders to Pegylated Interferon-α Therapy for Chronic Hepatitis B

    Article • Antiviral Therapy, October 2007, SAGE Publications

    Professor (Associate) Bart L. Haagmans

  338. Differential antiviral effect of PEG-interferon-??-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients

    Article • AIDS, September 2007, Wolters Kluwer Health

    Professor (Associate) Bart L. Haagmans

  339. Characterization of Hepatitis C Virus Deletion Mutants Circulating in Chronically Infected Patients

    Article • Journal of Virology, August 2007, ASM Journals

    Professor (Associate) Bart L. Haagmans

  340. [520] PREDICTION OF SUSTAINED ALT NORMALIZATION BY VIRAL LOAD DURING PEG-IFN ALPHA-2b TREATMENT FOR HBeAg-POSITIVE CHRONIC HEPATITIS B

    Article • Journal of Hepatology, April 2007, Elsevier

    Professor (Associate) Bart L. Haagmans

  341. P1889 Pharmacokinetic profiles in chronic hepatitis C patients treated with high-dose pegylated interferon

    Article • International Journal of Antimicrobial Agents, March 2007, Elsevier

    Professor (Associate) Bart L. Haagmans

  342. Functional Genomics Highlights Differential Induction of Antiviral Pathways in the Lungs of SARS-CoV–Infected Macaques

    Article • PLoS Pathogens, January 2007, PLOS

    Professor (Associate) Bart L. Haagmans

  343. The emerging role of ACE2 in physiology and disease

    Article • The Journal of Pathology, January 2007, Wiley

    Professor (Associate) Bart L. Haagmans

  344. Mycophenolic Acid Inhibits Hepatitis C Virus Replication and Acts in Synergy With Cyclosporin A and Interferon-α

    Article • Gastroenterology, November 2006, Elsevier

    Professor (Associate) Bart L. Haagmans

  345. Interferon (IFN)–γ–Inducible Protein–10: Association with Histological Results, Viral Kinetics, and Outcome during Treatment with Pegylated IFN‐α2a and Ribavirin for Chronic Hepatitis C Virus Infection

    Article • The Journal of Infectious Diseases, October 2006, Oxford University Press (OUP)

    Professor (Associate) Bart L. Haagmans

  346. Novel in-vitro and in vivo models

    Article • PLoS Medicine, September 2006, PLOS

    Professor (Associate) Bart L. Haagmans

  347. Genotyping Hepatitis C Viruses from Southeast Asia by a Novel Line Probe Assay That Simultaneously Detects Core and 5' Untranslated Regions

    Article • Journal of Clinical Microbiology, September 2006, ASM Journals

    Professor (Associate) Bart L. Haagmans

  348. Interferon-γ and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells

    Article • Virology, September 2006, Elsevier

    Professor (Associate) Bart L. Haagmans

  349. Coronaviruses and their therapy

    Article • Antiviral Research, September 2006, Elsevier

    Professor (Associate) Bart L. Haagmans

  350. Identification of a Naturally Occurring Recombinant Genotype 2/6 Hepatitis C Virus

    Article • Journal of Virology, August 2006, ASM Journals

    Professor (Associate) Bart L. Haagmans

  351. Nonhuman Primate Models for SARS

    Article • PLoS Medicine, April 2006, PLOS

    Professor (Associate) Bart L. Haagmans

  352. Antibodies Neutralizing Peginterferon Alfa during Retreatment of Hepatitis C

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, March 2006, New England Journal of Medicine (NEJM/MMS)

    Professor (Associate) Bart L. Haagmans

  353. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response

    Article • Hepatology, January 2006, Wiley

    Professor (Associate) Bart L. Haagmans

  354. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection

    Article • Hepatology, January 2006, Wiley

    Professor (Associate) Bart L. Haagmans

  355. Virus Specific Immune Responses after Human Neoadjuvant Adenovirus-mediated Suicide Gene Therapy for Prostate Cancer

    Article • European Urology, July 2005, Elsevier

    Professor (Associate) Bart L. Haagmans

  356. Immunisation with virion-loaded plasmacytoid or myeloid dendritic cells induces primary Th-1 immune responses

    Article • Vaccine, February 2005, Elsevier

    Professor (Associate) Bart L. Haagmans

  357. Monitoring intrahepatic CD8+ T cells by fine-needle aspiration cytology in chronic hepatitis C infection

    Article • Journal of Viral Hepatitis, July 2004, Wiley

    Professor (Associate) Bart L. Haagmans

  358. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets

    Article • The Lancet, June 2004, Elsevier

    Professor (Associate) Bart L. Haagmans

  359. Host-dependent type 1 cytokine responses driven by inactivated viruses may fail to default in the absence of IL-12 or IFN- / 

    Article • Journal of General Virology, April 2004, Society for General Microbiology

    Professor (Associate) Bart L. Haagmans

  360. Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques

    Article • Nature Reports Stem Cells, February 2004, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  361. 848 Neoadjuvant prostate cancer gene therapy: Clinical and pre-clinical results

    Article • European Urology Supplements, February 2004, Elsevier

    Professor (Associate) Bart L. Haagmans

  362. 494 Analysis of peripheral HCV-specific T cell responses associated with rapid viral decline during PEG-interferon-alfa-2A and ribavirin therapy (DITTO-HCV project)

    Article • Journal of Hepatology, January 2004, Elsevier

    Professor (Associate) Bart L. Haagmans

  363. Pretreatment Intrahepatic CD8 + Cell Count Correlates with Virological Response to Antiviral Therapy in Chronic Hepatitis C Virus Infection

    Article • The Journal of Infectious Diseases, November 2003, Oxford University Press (OUP)

    Professor (Associate) Bart L. Haagmans

  364. SARS virus infection of cats and ferrets

    Article • Nature, October 2003, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  365. Prostate cancer gene therapy: Preliminary clinical and pre-clinical results

    Article • European Urology Supplements, September 2003, Elsevier

    Professor (Associate) Bart L. Haagmans

  366. Prostate cancer gene therapy: Preliminary clinical and pre-clinical results

    Article • European Urology Supplements, September 2003, Elsevier

    Professor (Associate) Bart L. Haagmans

  367. The glycosylation status of the murine hepatitis coronavirus M protein affects the interferogenic capacity of the virus in vitro and its ability to replicate in the liver but not the brain

    Article • Virology, August 2003, Elsevier

    Professor (Associate) Bart L. Haagmans

  368. A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C

    Article • Journal of Virological Methods, June 2003, Elsevier

    Professor (Associate) Bart L. Haagmans, Ralf Bartenschlager

  369. Comparative study of different methods to genotype hepatitis C virus type 6 variants

    Article • Journal of Virological Methods, May 2003, Elsevier

    Professor (Associate) Bart L. Haagmans

  370. Pretreatment intrahepatic CD8+ cell number correlates with virological response to antiviral therapy in chronic hepatitis C

    Article • Journal of Hepatology, April 2003, Elsevier

    Professor (Associate) Bart L. Haagmans

  371. Molecular epidemiology of gibbon hepatitis B virus transmission

    Article • Journal of General Virology, January 2003, Society for General Microbiology

    Professor (Associate) Bart L. Haagmans

  372. Rat testicular germ & sertoli cells release different types of bioactive TGF-β in vitro

    Article • Reproductive Biology and Endocrinology, January 2003, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans

  373. Protective Antiviral Immune Responses to Pseudorabies Virus Induced by DNA Vaccination Using Dimethyldioctadecylammonium Bromide as an Adjuvant

    Article • Journal of Virology, October 2002, ASM Journals

    Professor (Associate) Bart L. Haagmans

  374. DITTO-HCV early viral kinetics report - novel decline patterns in gen 1 but not gen 2–3 patients treated with PEG-interferon-alfa-2a and ribavirin

    Article • Journal of Hepatology, April 2002, Elsevier

    Professor (Associate) Bart L. Haagmans

  375. Long-term HBV kinetics classification during treatment with adefovir dipivoxil

    Article • Journal of Hepatology, April 2002, Elsevier

    Professor (Associate) Bart L. Haagmans

  376. Identification and characterisation of adenovirus specific T cell responses in prostate cancer patients receiving ADV5-RSV-TK gene therapy

    Article • European Urology Supplements, January 2002, Elsevier

    Professor (Associate) Bart L. Haagmans

  377. Adverse effects of feline IL-12 during DNA vaccination against feline infectious peritonitis virus

    Article • Journal of General Virology, January 2002, Society for General Microbiology

    Professor (Associate) Bart L. Haagmans

  378. Corrigendum to “A DNA vaccine coding for glycoprotein B of pseudorabies virus induces cell-mediated immunity in pigs and reduces virus excretion early after infection” [Vet. Immunol. Immunopathol. 74 (2000) 121–136]

    Article • Veterinary Immunology and Immunopathology, June 2000, Elsevier

    Professor (Associate) Bart L. Haagmans

  379. Foreign-body reaction to dermal sheep collagen in interferon-?-receptor knock-out mice

    Article • Journal of Biomedical Materials Research, May 2000, Wiley

    Professor (Associate) Bart L. Haagmans

  380. A DNA vaccine coding for glycoprotein B of pseudorabies virus induces cell-mediated immunity in pigs and reduces virus excretion early after infection

    Article • Veterinary Immunology and Immunopathology, April 2000, Elsevier

    Professor (Associate) Bart L. Haagmans

  381. Cytokine mRNAs in liver biopsy samples predict complete virus eradication with interferon-α ribavirin treatment in chronic hepatitis

    Article • European Journal of Gastroenterology & Hepatology, December 1999, Wolters Kluwer Health

    Professor (Associate) Bart L. Haagmans

  382. Vaccination of pigs against pseudorabies virus with plasmid DNA encoding glycoprotein D

    Article • Vaccine, March 1999, Elsevier

    Professor (Associate) Bart L. Haagmans

  383. Effect of vaccination route and composition of DNA vaccine on the induction of protective immunity against pseudorabies infection in pigs

    Article • Veterinary Immunology and Immunopathology, November 1998, Elsevier

    Professor (Associate) Bart L. Haagmans

  384. Mice Lacking IL-12 Develop Polarized Th1 Cells During Viral Infection

    Article • The Journal of Immunology, April 1998, The American Association of Immunologists

    Professor (Associate) Bart L. Haagmans

  385. Persistence and Evolution of Feline Coronavirus in a Closed Cat-Breeding Colony

    Article • Virology, August 1997, Elsevier

    Professor (Associate) Bart L. Haagmans

  386. Neutrophil induced T-cell apoptosis during a viral infection

    Article • Immunology Letters, May 1997, Elsevier

    Professor (Associate) Bart L. Haagmans

  387. Neutrophil induced T-cell apoptosis during a viral infection

    Article • Immunology Letters, May 1997, Elsevier

    Professor (Associate) Bart L. Haagmans

  388. Virus-induced type-1 cytokine response in IL-12 deficient mice

    Article • Immunology Letters, May 1997, Elsevier

    Professor (Associate) Bart L. Haagmans

  389. Vaccination of pigs with plasmid DNA coding for glycoproteins of pseudorables virus provides protection against challenge infection with pseudorables virus

    Article • Immunology Letters, May 1997, Elsevier

    Professor (Associate) Bart L. Haagmans

  390. Transforming growth factor beta production during rat cytomegalovirus infection.

    Article • Journal of General Virology, January 1997, Society for General Microbiology

    Professor (Associate) Bart L. Haagmans

  391. Apoptosis and T-cell depletion during feline infectious peritonitis.

    Article • Journal of Virology, January 1996, ASM Journals

    Professor (Associate) Bart L. Haagmans

  392. Tumour necrosis factor-  production during cytomegalovirus infection in immunosuppressed rats

    Article • Journal of General Virology, April 1994, Society for General Microbiology

    Professor (Associate) Bart L. Haagmans

  393. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees

    Article • Blood, January 1994, American Society of Hematology

    Professor (Associate) Bart L. Haagmans

  394. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees

    Article • Blood, January 1994, American Society of Hematology

    Professor (Associate) Bart L. Haagmans

  395. Suppression of rat cytomegalovirus replication by antibodies against gamma interferon.

    Article • Journal of Virology, January 1994, ASM Journals

    Professor (Associate) Bart L. Haagmans

  396. Tumor necrosis factor alpha promotes replication and pathogenicity of rat cytomegalovirus.

    Article • Journal of Virology, January 1994, ASM Journals

    Professor (Associate) Bart L. Haagmans

  397. Tumor necrosis factor α levels in cats experimentally infected with feline immunodeficiency virus: effects of immunization and feline leukemia virus infection

    Article • Veterinary Immunology and Immunopathology, December 1992, Elsevier

    Professor (Associate) Bart L. Haagmans

  398. Pneumococcal conjugate vaccines

    Article • Immunology Letters, October 1991, Elsevier

    Professor (Associate) Bart L. Haagmans, Prof Ger T Rijkers

  399. Tumour necrosis factor- , interferon-  and interferon-beta exert antiviral activity in nervous tissue cells

    Article • Journal of General Virology, April 1991, Society for General Microbiology

    Professor (Associate) Bart L. Haagmans

  400. Protection of Rats against Pseudorabies Virus Infection by  -Interferon

    Article • Experimental Biology and Medicine, October 1989, SAGE Publications

    Professor (Associate) Bart L. Haagmans